Latest Conference Articles

Charu Aggarwal, MD, MPH, discusses the current state of treatment for patients with ALK-positive non–small cell lung cancer, the utility of liquid biopsy, and remaining questions that need to be addressed in the space.

Although antibody-drug conjugates have yet to receive regulatory approval in the lung cancer space, several emerging agents are showing early promise in clinical trials.

Clinical data shows that the TRK inhibitors entrectinib and larotrectinib induce high response rates with favorable toxicity profiles and central nervous system penetration, and are a viable treatment option for patients with advanced TRK fusion-positive cancers.

Ignacio I. Wistuba, MD, discusses the clinical importance of histological subtyping of lung cancer and additional parameters such as driver alterations, alternative methods for molecular testing, and immunotherapy-related biomarkers have strengthened the diagnostic and treatment paradigms in lung cancer.

In non–small cell lung cancer, single cell analytics, genome editing, and next-generation animal models represent just some of the modern modalities advancing translational research.

The disease-free survival benefit observed with the third-generation EGFR TKI osimertinib as an adjuvant treatment in patients with EGFR-mutant non–small cell lung cancer in the phase 3 ADAURA trial is striking.

Charu Aggarwal, MD, MPH, discusses emerging treatment approaches in ALK-positive non–small cell lung cancer.

David R. Gandara, MD, discusses the utility of tumor mutational burden in non–small cell lung cancer.

Angela DeMichele, MD, MSCE, shares how to utilize available data with CDK4/6 inhibitors in the neoadjuvant and adjuvant settings to optimize outcomes for patients with hormone receptor–positive breast cancer.

Terry P. Mamounas, MD, MPH, FACS, discusses common recurrence rates in breast cancer.

The growing number of treatments within the HER2-positive breast cancer armamentarium signals a need to redefine and tailor neoadjuvant and adjuvant strategies to individual patients.

Sara M. Tolaney, MD, MPH, discusses appropriately deescalating treatment to reduce toxicities in stage I HER2-positive breast cancer.

The optimal sequence of therapies for patients with metastatic HER2-positive breast cancer must be an individualized one, and should be dependent on the presence and/or level of central nervous system disease.

Despite the influx of novel agents that have received regulatory approval in recent years in stem cell disorders, there is still room for improvement.

As part of the 2020 ASCO Direct Highlights™ webcast, Brian Rini, MD, discusses key developments in genitourinary cancers that were presented during the 2020 ASCO Virtual Scientific Program.

A panel of experts in acute lymphoblastic leukemia broach the topic of innovative approaches incorporating novel agents in clinical practice.

A panel of experts in acute myeloid leukemia (AML) consider potential treatment options for patients with AML

A panel of experts in chronic myeloid leukemia share insight on how to optimally approach treatment based on patient characteristics.

Noopur Raje, MD, discusses the current challenges faced in the multiple myeloma treatment paradigm.

Lori Leslie, MD, discusses key questions to address with future research efforts in mantle cell lymphoma.

Immunotherapy and BRAF plus MEK inhibition are the key players in the treatment of patients with melanoma, Michael Postow, MD, said in a presentation during the 2020 ASCO Direct Highlights webcast.

The treatment landscape of advanced hepatocellular carcinoma has been subject to rapid development in the last few years, says Amit G. Singal, MD, MS.

The 2020 ASCO Virtual Scientific Program delivered a number of important updates to the field of breast cancer, explained Joyce A. O'Shaughnessy, MD.

Richard D. Kim, MD, discusses the efficacy of and next steps for a phase 1/1b study with regorafenib and nivolumab in patients with mismatch repair proficient advanced refractory colorectal cancer.

Infigratinib conferred a clinically meaningful progression-free survival and overall response rate benefit when administered as a third- and later-line treatment for patients with FGFR2 fusion–positive cholangiocarcinoma.

Zev. A. Wainberg, MD, discusses findings from a phase 1/2 study of NALIRIFOX in patients with pancreatic ductal adenocarcinoma.

EDP1503, an investigational monoclonal microbial product, was safe and well-tolerated when administered in combination with pembrolizumab (Keytruda), and mechanistically drove some of the patient responses seen in a phase 1/2 study.

Harry H. Yoon, MD, discusses the updated results of the phase 3 KEYNOTE-061 trial in advanced gastric/gastroesophageal junction (GEJ) cancer.

Irinotecan monotherapy demonstrated similar clinical activity and improved safety compared with capecitabine plus irinotecan in patients with advanced gallbladder cancer, representing a potential second-line treatment for frail patients.

Anant Ramaswamy, MD, discusses a phase 2 multicenter clinical trial evaluating the efficacy of capecitabine plus irinotecan versus irinotecan monotherapy in advanced gallbladder cancer.